DK1105460T3 - Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf - Google Patents
Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser derafInfo
- Publication number
- DK1105460T3 DK1105460T3 DK99942066.4T DK99942066T DK1105460T3 DK 1105460 T3 DK1105460 T3 DK 1105460T3 DK 99942066 T DK99942066 T DK 99942066T DK 1105460 T3 DK1105460 T3 DK 1105460T3
- Authority
- DK
- Denmark
- Prior art keywords
- producing cells
- insulin producing
- exendin
- glp
- insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 14
- 102000004877 Insulin Human genes 0.000 title abstract 7
- 108090001061 Insulin Proteins 0.000 title abstract 7
- 229940125396 insulin Drugs 0.000 title abstract 7
- 108010011459 Exenatide Proteins 0.000 title abstract 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 title abstract 3
- 229960001519 exenatide Drugs 0.000 title abstract 3
- 230000004069 differentiation Effects 0.000 title 1
- 239000003102 growth factor Substances 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9591798P | 1998-08-10 | 1998-08-10 | |
| PCT/US1999/018099 WO2000009666A2 (en) | 1998-08-10 | 1999-08-10 | Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1105460T3 true DK1105460T3 (da) | 2010-02-08 |
Family
ID=22254191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99942066.4T DK1105460T3 (da) | 1998-08-10 | 1999-08-10 | Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7056734B1 (da) |
| EP (2) | EP1105460B1 (da) |
| JP (4) | JP4624558B2 (da) |
| AT (1) | ATE445006T1 (da) |
| AU (1) | AU776514B2 (da) |
| CA (1) | CA2339326A1 (da) |
| DE (1) | DE69941510D1 (da) |
| DK (1) | DK1105460T3 (da) |
| ES (2) | ES2553108T3 (da) |
| WO (1) | WO2000009666A2 (da) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138486B2 (en) * | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6703017B1 (en) | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| US6699973B1 (en) * | 1998-11-19 | 2004-03-02 | Elan Corporation, Plc | Antibodies to peptides that target GIT receptors and related methods |
| US6242666B1 (en) * | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
| US6967019B2 (en) * | 1999-04-06 | 2005-11-22 | The Regents Of The University Of California | Production of pancreatic islet cells and delivery of insulin |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US20030082155A1 (en) * | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| US6448045B1 (en) * | 2000-03-10 | 2002-09-10 | The Regents Of The University Of California | Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| EP1346722B1 (en) | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
| JP2005501058A (ja) | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Glp−1、exendin−4、そのペプチド・アナログ及びその使用 |
| US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
| US6911324B2 (en) | 2001-10-18 | 2005-06-28 | The Regents Of The University Of California | Induction of beta cell differentiation in human cells |
| EP1453954A4 (en) * | 2001-11-09 | 2004-12-15 | Artecel Sciences Inc | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| CA2476589C (en) * | 2002-02-27 | 2014-02-25 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
| US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
| US20060122104A1 (en) * | 2002-05-28 | 2006-06-08 | Presnell Sharon C | Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells |
| US7427415B2 (en) | 2002-10-11 | 2008-09-23 | Novocell, Inc. | Implantation of encapsulated biological materials for treating diseases |
| AU2003283216A1 (en) * | 2002-12-03 | 2004-06-23 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
| EP1688148A1 (en) * | 2002-12-03 | 2006-08-09 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ATE502665T1 (de) | 2003-02-04 | 2011-04-15 | Novo Nordisk As | Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| ATE437941T1 (de) * | 2003-06-20 | 2009-08-15 | Vrije Universiteit Brussel Vub | Verfahren zur erzeugung von beta-inselzellen aus exokrinen pankreaszellen |
| US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| ES2564044T3 (es) | 2003-06-27 | 2016-03-17 | DePuy Synthes Products, Inc. | Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas |
| US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | 4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| PT1723128E (pt) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| WO2005112977A2 (en) * | 2004-04-23 | 2005-12-01 | Pharmain, Ltd. | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| JPWO2005118781A1 (ja) * | 2004-06-03 | 2008-04-03 | 国立大学法人京都大学 | インスリン分泌細胞の誘導 |
| US8148412B2 (en) | 2004-12-03 | 2012-04-03 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
| BRPI0612996A2 (pt) | 2005-07-14 | 2010-12-14 | Novo Nordisk As | ativadores de urÉia glucocinase |
| AU2006290205B2 (en) | 2005-09-14 | 2012-12-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN101374946B (zh) | 2005-12-16 | 2017-07-18 | 伊西康公司 | 用于在组织相容性不匹配的移植中抑制有害的免疫反应的组合物和方法 |
| EP1971372B1 (en) | 2005-12-19 | 2018-11-14 | PharmaIN Corporation | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
| US8178495B2 (en) | 2008-06-27 | 2012-05-15 | Duke University | Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide |
| US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
| US20090054305A1 (en) | 2006-03-15 | 2009-02-26 | Novo Nordisk A/S | Mixtures of Amylin and Insulin |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
| RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| US20100216691A1 (en) | 2007-07-16 | 2010-08-26 | Novo Nordisk A/S | Protease Stabilized, Pegylated Insulin Analogues |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
| US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
| WO2009109927A2 (en) * | 2008-03-05 | 2009-09-11 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
| WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| BRPI0923068B1 (pt) | 2008-12-19 | 2021-05-25 | Advanced Technologies And Regenerative Medicine, Llc | Uso de células derivadas de tecido de cordão umbilical para tratar um paciente tendo uma doença, distúrbio ou injúria pulmonar |
| US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| CN102498204B (zh) | 2009-03-26 | 2015-02-04 | 德普伊新特斯产品有限责任公司 | 人脐带组织细胞作为用于阿尔茨海默病的疗法 |
| CN101991580B (zh) * | 2009-08-28 | 2013-03-20 | 杏辉天力(杭州)药业有限公司 | 以羊毛甾烷及茯苓萃取物治疗糖尿病的用途 |
| WO2011064316A2 (en) | 2009-11-25 | 2011-06-03 | Paolo Botti | Mucosal delivery of peptides |
| CA2797133C (en) | 2010-04-27 | 2019-08-06 | Zealand Pharma A/S | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
| CN109593814A (zh) | 2010-05-12 | 2019-04-09 | 哥伦比亚大学纽约管理委员会 | 筛选分析、鉴别药剂的方法及药物组合物 |
| TW201326194A (zh) | 2011-11-03 | 2013-07-01 | Zealand Pharma As | Glp-1胃泌素受體促效劑肽結合物 |
| JP6301263B2 (ja) | 2011-12-23 | 2018-03-28 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | ヒト臍帯組織由来細胞の検出 |
| MX356957B (es) | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| JP2016506401A (ja) | 2012-12-21 | 2016-03-03 | サノフイ | 二重glp1/gipまたは三方glp1/gip/グルカゴンアゴニストとしてのエキセンジン−4誘導体 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| LT3057984T (lt) | 2013-10-17 | 2018-12-27 | Zealand Pharma A/S | Acilinti gliukagono analogai |
| AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-glp-1-gip 삼원 효능제 화합물 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| WO2015162485A1 (en) * | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Peptide analogues with branched amino acid probe(s) |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
| RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
| RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
| JP6989385B2 (ja) | 2015-04-16 | 2022-01-05 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
| SG10201911851VA (en) | 2016-12-09 | 2020-02-27 | Zealand Pharma As | Acylated glp-1/glp-2 dual agonists |
| CN109679964A (zh) * | 2019-01-12 | 2019-04-26 | 青岛华义宏博生物科技有限公司 | 一种表达人胰岛素基因的重组乳酸乳球菌 |
| EP3938037A1 (en) | 2019-03-15 | 2022-01-19 | Diet4Life ApS | Combination of dietary peptides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| AU4114493A (en) * | 1992-04-24 | 1993-11-29 | Polymer Technology Group, Inc., The | Method of culturing viable cells and method of regulating the level of a compound in a body fluid |
| SK155694A3 (en) | 1992-06-15 | 1995-05-10 | Pfizer | Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters |
| NZ250844A (en) | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| DE69739172D1 (de) * | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
| WO1999043705A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
-
1999
- 1999-08-10 JP JP2000565103A patent/JP4624558B2/ja not_active Expired - Fee Related
- 1999-08-10 EP EP99942066A patent/EP1105460B1/en not_active Expired - Lifetime
- 1999-08-10 ES ES08019260.2T patent/ES2553108T3/es not_active Expired - Lifetime
- 1999-08-10 CA CA002339326A patent/CA2339326A1/en not_active Abandoned
- 1999-08-10 WO PCT/US1999/018099 patent/WO2000009666A2/en not_active Ceased
- 1999-08-10 EP EP08019260.2A patent/EP2028269B1/en not_active Expired - Lifetime
- 1999-08-10 US US09/762,538 patent/US7056734B1/en not_active Expired - Fee Related
- 1999-08-10 ES ES99942066T patent/ES2335066T3/es not_active Expired - Lifetime
- 1999-08-10 AU AU55524/99A patent/AU776514B2/en not_active Ceased
- 1999-08-10 AT AT99942066T patent/ATE445006T1/de active
- 1999-08-10 DK DK99942066.4T patent/DK1105460T3/da active
- 1999-08-10 DE DE69941510T patent/DE69941510D1/de not_active Expired - Lifetime
-
2006
- 2006-04-07 US US11/400,715 patent/US20070041951A1/en not_active Abandoned
-
2007
- 2007-04-24 JP JP2007114374A patent/JP4755133B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-07 JP JP2009184807A patent/JP2009291206A/ja active Pending
-
2011
- 2011-04-05 JP JP2011083828A patent/JP2011177181A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2335066T3 (es) | 2010-03-18 |
| WO2000009666A3 (en) | 2000-11-23 |
| CA2339326A1 (en) | 2000-02-24 |
| JP2002522068A (ja) | 2002-07-23 |
| US20070041951A1 (en) | 2007-02-22 |
| US7056734B1 (en) | 2006-06-06 |
| JP2007209348A (ja) | 2007-08-23 |
| JP4624558B2 (ja) | 2011-02-02 |
| DE69941510D1 (de) | 2009-11-19 |
| ES2553108T3 (es) | 2015-12-04 |
| EP1105460B1 (en) | 2009-10-07 |
| JP2011177181A (ja) | 2011-09-15 |
| EP2028269B1 (en) | 2015-10-21 |
| EP2028269A1 (en) | 2009-02-25 |
| JP4755133B2 (ja) | 2011-08-24 |
| ATE445006T1 (de) | 2009-10-15 |
| AU776514B2 (en) | 2004-09-09 |
| WO2000009666A9 (en) | 2000-07-13 |
| AU5552499A (en) | 2000-03-06 |
| JP2009291206A (ja) | 2009-12-17 |
| EP1105460A2 (en) | 2001-06-13 |
| WO2000009666A2 (en) | 2000-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000009666A3 (en) | Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof | |
| DK0518587T3 (da) | A-B-C-proinsulin, fremgangsmåde til fremstilling og anvendelse af samme og mellemprodukter ved insulinfremstilling | |
| WO2003014318A3 (en) | Methods for treating diabetes and other blood sugar disorders | |
| DK0670896T3 (da) | Kloning og ekspression af biologisk aktivt alfa-galactosidase A | |
| EG19101A (en) | Process for preparing of expression of human proapolipoprotein A.1. | |
| DE69119454D1 (de) | DNA-Fragment, das ein Polypeptid mit Nitrilhydrataseaktivität kodiert, DNA-Fragment enthaltende Transformante und Verfahren zur Herstellung von Amiden unter Verwendung der Transformante | |
| DE3583194D1 (de) | Verfahren zur herstellung von einem polypeptid mittels eines transformierten mikroorganismus, ein dazu geeigneter transformierter mikroorganismus, und zur herstellung dieser mikroorganismen geeignete dns sequenzen. | |
| ATE454396T1 (de) | Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure | |
| BR9710665A (pt) | Compostos que promovem o desenvolvimento do tecido | |
| DE69940984D1 (de) | Verfahren zur Milderung von Schädlingsverseuchung von Pflanzen | |
| DE59712555D1 (de) | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
| ATE401413T1 (de) | Verfahren zur herstellung von l-aminosäuren, unter verwendung von stämmen aus der familie der enterobacteriaceae, welche ein attenuiertes acea- gen enthalten | |
| DE69626034D1 (de) | Zusammensetzung für verbesserung der pankreasfunktion | |
| ES2063834T3 (es) | Tgf-beta 1/beta 2: un nuevo factor del crecimiento-beta transformante quimerico. | |
| DK0458386T3 (da) | Fremgangsmåde til fremstilling af stabile bitumen-polymerblandinger | |
| ATE263246T1 (de) | Verfahren zur fermentativen herstellung von l- aminosäuren unter verwendung coryneformer bakterien | |
| DK120290D0 (da) | Nye derivater af human/bovin basal fibroblastvaekstfaktor | |
| JPS5788016A (en) | Optically anisotropic carbonaceous pitch for carbon material, its manufacture, and manufacture of carbonaceous pitch fiber and carbon fiber | |
| ATE233815T1 (de) | Mutanten der formiatdehydrogenase aus candida biodinii, gensequenzen diese codierend sowie verwendung dieser formiatdeydrogenasen | |
| WO2004035615A3 (en) | Factor involved in metastasis and uses thereof | |
| DE69530647D1 (de) | Für biosynthetische Insulinvorstufen kodierende DNA-Sequenzen und Verfahren zur Herstellung von Insulin | |
| HK1200874A1 (en) | Process for preparing insulin | |
| DK0672124T3 (da) | Anvendelse af en DNA-sekvens, der koder for et oxalsyre-nedbrydende protein i form af et selektionsgen | |
| DK0440989T3 (da) | Fremgangsmåde til fremstilling af et tørret præparat indeholdende insulin-lignende vækstfaktor I (IGF-I) | |
| DK0828004T3 (da) | Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær |